cms.bioaccessla.com

Blog

  • Clinical trial contract: what every key clause covers

    Clinical trial contract: what every key clause covers

    A clinical trial contract (CTA) is the legally binding agreement between a sponsor, a CRO, and an investigative site that governs how a study is run. Its key clauses cover confidentiality, intellectual property, indemnification, subject-injury coverage, and publication rights, each allocating risk and responsibility before a single patient is enrolled.

    Negotiating a CTA is one of the most time-intensive steps in study startup. Missing or poorly drafted clauses create regulatory and financial exposure that surfaces at the worst possible moment, often mid-enrollment. This article covers the five clause areas most likely to cause delays or disputes so you can spot gaps in a draft before they become problems.

    How long does clinical trial contract negotiation actually take?

    Longer than most sponsors budget for. According to The Contract Network's 2025 industry report, average CTA negotiations now exceed 90 days. A study of 78 sites found the median time to reach a fully signed CTA in EU countries reaches 183 days.

    The main drivers of delay are misaligned indemnification language, unresolved IP ownership, and budget disputes that require protocol-level changes. Each of those issues traces back to a clause that was left vague or skipped in the first draft.

    Before you open negotiations, use a clinical trial cost calculator to model per-patient costs and timeline milestones. Having those figures in hand before you sit down with a site keeps budget discussions grounded and shortens the back-and-forth on payment terms.

    Note: the 183-day figure above reflects EU site contracting specifically. US and Latin American timelines vary and depend on site experience, regulatory pathway, and sponsor preparedness.

    Step 1: Define the preamble and identify all contracting parties

    The preamble establishes the trial agreement meaning: who is bound, under what authority, and for what study. It names the sponsor, the CRO (if one is acting as the sponsor's agent), and the investigative site, and it recites the study protocol number and title.

    A common drafting error is omitting a sub-CRO or a site management organization that will perform material obligations. If that entity is not named in the preamble and listed in the definitions section, you cannot enforce performance obligations against it directly. Every entity that will handle study data, manage patients, or submit regulatory documents should appear as a named party or a defined third-party contractor with explicit obligations attached.

    The definitions section, which follows the recitals, should also define "confidential information," "study data," "background IP," and "foreground IP" before those terms appear in substantive clauses. Leaving them undefined forces later interpretation disputes.

    Step 2: Set confidentiality and non-disclosure boundaries

    Confidentiality clauses in a CTA go beyond a standard NDA. They must specify which categories of information are protected, how long the obligation runs, and what happens to data when the agreement ends.

    For cross-border trials, data-transfer clauses require additional language. A study running in Panama, Chile, or Colombia that sends patient data to a US sponsor must address the applicable data-protection rules of each country. That means naming the transfer mechanism, specifying data formats, and stating who acts as data controller versus data processor. Without that language, a site's ethics committee may flag the agreement before approval.

    Survival is the other critical issue. Confidentiality obligations must explicitly survive termination. State the survival period in years (five years is common for study data; indefinite for trade secrets), and list the specific obligations that continue: record retention, data destruction or return procedures, and restrictions on publication of confidential methodology.

    Step 3: Allocate intellectual property rights for study data and inventions

    Sponsors typically claim ownership of all study data and any foreground inventions arising from the trial. Sites and investigators typically retain rights to their background IP, meaning the methods, tools, and knowledge they brought into the study. The CTA must draw that line clearly.

    Background IP should be defined by reference to a schedule attached to the agreement, listing what the site or investigator owns going in. Foreground IP, anything created during the study using sponsor resources or sponsor data, should vest in the sponsor automatically, with a license-back to the site for non-commercial academic use if the site requires it.

    Investigator-initiated trials complicate this split. When the investigator originates the hypothesis and the sponsor only funds execution, ownership of the resulting data and any patentable invention is actively contested. The CTA must specify whether the sponsor receives an exclusive or non-exclusive license, whether that license is royalty-bearing, and how inventorship disputes are resolved. Leaving this to a handshake creates litigation risk at the point of commercialization.

    Step 4: Differentiate indemnification from subject-injury coverage

    These two clauses address different risk pools and should never be merged into a single provision.

    Indemnification covers third-party claims arising from a party's negligence or breach. The sponsor typically indemnifies the site for claims arising from the protocol design; the site indemnifies the sponsor for claims arising from the investigator's conduct. Each indemnity should state its trigger, its cap (or confirm it is uncapped), and its notice and cooperation requirements.

    Subject-injury coverage is separate. It addresses what happens when a trial participant is harmed, regardless of fault. Good clinical practice standards require that subjects receive medical treatment for trial-related injuries without cost to them. The CTA must state who pays for that treatment, whether a clinical-trial insurance policy is in place, and what the policy limits are. The CTA must name the sponsor's and site's monitoring and safety responsibilities explicitly rather than defaulting to "as required by applicable law," so that liability can be assigned if something goes wrong.

    Country-specific frameworks add further requirements. Some national regulators require specific indemnification language or mandatory insurance minimums as a condition of ethics committee approval. According to Pennington's Law's 2026 analysis, the average combined regulatory and ethical review in the UK has decreased to 41 days, partly because standardized indemnification templates have reduced negotiation cycles. The lesson applies broadly: pre-agreed indemnification language speeds approval regardless of jurisdiction. For a deeper look at liability structures in cross-border device trials, see International Clinical Trial Liability for a Medical Device FIH.

    Step 5: Define publication rights and mandatory hold periods

    Publication clauses protect the sponsor's ability to file patents and review data before results go public, while preserving the investigator's academic freedom. Both interests are legitimate. The clause must balance them explicitly.

    A standard structure includes:

    1. Notification period. The investigator notifies the sponsor at least 30 to 60 days before submitting a manuscript or abstract.
    2. Sponsor review window. The sponsor has a defined period, typically 30 to 45 days, to review for confidential information and patentable inventions.
    3. Hold period for patent filing. If the sponsor identifies a patentable invention, the publication is delayed by an additional period, commonly 60 to 90 days, to allow a patent application to be filed.
    4. Removal of confidential information. The sponsor may require deletion of confidential methodology but may not suppress negative results or alter scientific conclusions.
    5. Survival. Publication obligations survive contract termination. State this explicitly, including the duration of the hold period after termination.

    For an accelerated clinical trial agreement, sponsors sometimes negotiate a compressed review window of 15 to 20 days in exchange for pre-approving a publication plan at contract execution. That trade-off works when the protocol is narrow and the IP landscape is well-mapped in advance.

    When does a CRO help you negotiate and close a clinical trial contract faster?

    A CRO with established site relationships can compress contracting timelines significantly. Sites that have already executed a master agreement with a CRO often accept work orders rather than full CTAs for each new study, cutting negotiation cycles from months to weeks. According to ZipDo's 2026 industry data, the average CRO fee for a phase III trial runs approximately 12% of total budget, presented here as an industry reference point rather than a fixed rate, and not applicable to first-in-human or early-feasibility studies where scope differs substantially.

    bioaccess® is a Miami-headquartered CRO serving MedTech, biopharma, and radiopharma sponsors. Its FIH-12™ program covers the full nine-workstream engagement from FDA Pre-Sub and IDE/IND pathway alignment through protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package, all within a 12-month structure.

    Median phase III recruitment reached 11.2 months in 2023, according to ZipDo's data, which underscores why site contracting speed matters: delays in executing CTAs directly compress the enrollment window. To compare CRO options for your study type and geography, see the CRO comparison guide and the Best CROs for First-in-Human Device Trials in Latin America.

    FAQs

    A clinical trial contract is a legal agreement between institutional parties, the sponsor, CRO, and site, that governs operations, liability, IP, and data. An informed consent form (ICF) is a participant-facing document that discloses study risks, procedures, and rights to the individual subject. The two documents serve different legal functions and are negotiated separately. The CTA governs the parties; the ICF governs the participant relationship.

    What clauses must survive termination of a clinical trial contract?

    At minimum, confidentiality obligations, record retention duties, subject-injury coverage for enrolled participants, IP ownership provisions, and publication hold periods must survive termination. State each surviving clause by name in a dedicated survival section rather than relying on a general "provisions that by their nature survive" catch-all, which courts interpret inconsistently.

    How does an accelerated clinical trial agreement differ from a standard CTA?

    An accelerated CTA uses pre-negotiated master terms, compressed review windows, and pre-approved publication plans to reduce the time from first draft to fully executed agreement. It works best when the sponsor and site have an existing relationship, the protocol is narrow in scope, and IP ownership is straightforward. Without those conditions, compressing timelines often shifts risk rather than eliminating it.

    What is the role of a CRO in site contract negotiation?

    A CRO with established site relationships can negotiate work orders against a pre-existing master agreement, bypassing full CTA redlines for each site. The CRO also ensures that indemnification language, insurance requirements, and data-transfer provisions meet both the sponsor's standards and the site's regulatory obligations. For first-in-human studies in Latin America, a local CRO with in-country legal knowledge is particularly valuable because national data-protection and insurance requirements vary by country.

    What payment and budget terms belong in a clinical trial contract?

    Payment clauses should specify the per-patient visit fee schedule, milestone-based payments tied to protocol events, and a holdback amount released after the final data lock. The agreement should also state the invoicing cycle, the currency, and the process for handling protocol amendments that change the agreed budget. Leaving payment terms to a separate letter of intent rather than the CTA itself creates disputes when scope changes mid-study.

    What termination and wind-down provisions should a CTA include?

    The termination section should cover both for-cause and convenience termination, stating the notice period for each. It must also address wind-down obligations: who completes ongoing patient visits, how site staff are paid for work performed after notice, and how study materials and data are returned or destroyed. A clear wind-down procedure prevents enrolled participants from losing access to care and limits the sponsor's financial exposure when a site exits mid-study.

    Conclusion

    A clinical trial contract allocates risk before a single patient is enrolled. Getting the preamble, confidentiality, IP, indemnification, and publication clauses right in the first draft shortens negotiation cycles and prevents the disputes that stall studies mid-execution.

    Audit your current draft against the five clause areas covered here: preamble and party identification, confidentiality and data transfer, IP ownership, indemnification and subject-injury coverage, and publication rights. If any clause is missing or defers entirely to "applicable law" without naming specific obligations, flag it for redline before the agreement goes to the site. For first-in-human or early-feasibility studies in Latin America, confirm that country-specific insurance requirements and data-transfer rules are addressed before submitting to an ethics committee.

  • George Clinical / Emerald Clinical Device Trials vs a Latin America First-in-Human CRO (bioaccess®)

    If you typed George Clinical (Emerald Clinical) into a search box, you are probably building a CRO shortlist. This article uses only what George Clinical (Emerald Clinical) publishes (georgesclinical.com/therapeutic-expertise/medical-devices-cro · emeraldclinical.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What George Clinical (Emerald Clinical) publishes

    George Clinical, which came out of Sydney's The George Institute, rebranded as Emerald Clinical in 2025. Its medical device page covers feasibility, pilot, Class II/III pivotal and post-market studies. It is a full-service CRO with 500+ people, 40 locations and 70 geographies, strongest in renal, cardiovascular and oncology late-phase work.

    George Clinical (Emerald Clinical) vs bioaccess®

    Dimension George Clinical (Emerald Clinical) bioaccess®
    Core focus APAC-origin full-service CRO, late-phase strength First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If the device program is a large pivotal or post-market study across Asia-Pacific, George / Emerald is a capable choice.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including George Clinical (Emerald Clinical), for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not George Clinical (Emerald Clinical) features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the George Clinical (Emerald Clinical) public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Biointelect Australia vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Biointelect into a search box, you are probably building a CRO shortlist. This article uses only what Biointelect publishes (www.biointelect.com/cro) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Biointelect publishes

    Biointelect is a Sydney consultancy founded in 2011 that added a CRO. It lists medical devices among its therapeutic areas, plus first-in-human, Phase I–II and high-risk inpatient studies, and leans toward strategy, local sponsor and regulatory work. Leah Goodman is CEO.

    Biointelect vs bioaccess®

    Dimension Biointelect bioaccess®
    Core focus Australian consulting + CRO + local sponsor First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If what you need is an Australian entity, local sponsor and R&D tax-incentive coordination around a Phase I unit, Biointelect fits.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Biointelect, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Biointelect features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Biointelect public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Datapharm Australia vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Datapharm Australia into a search box, you are probably building a CRO shortlist. This article uses only what Datapharm Australia publishes (datapharmaustralia.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Datapharm Australia publishes

    Datapharm Australia, in Drummoyne, Sydney, calls itself Australia's original full-service CRO, founded in 1987. Its therapeutic list includes devices, diagnostics and first-in-humans, and its cardiovascular page cites implants and stents. Helen Allars and John Edington are its co-founders.

    Datapharm Australia vs bioaccess®

    Dimension Datapharm Australia bioaccess®
    Core focus Mid-market single-country Australian CRO, drug and device First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a single-country Australian device or first-in-human study with a long-established local CRO, Datapharm fits.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Datapharm Australia, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Datapharm Australia features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Datapharm Australia public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • iNGENū CRO Melbourne vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed iNGENū CRO into a search box, you are probably building a CRO shortlist. This article uses only what iNGENū CRO publishes (ingenucro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What iNGENū CRO publishes

    iNGENū CRO is a Melbourne, physician-led biotech CRO led by CEO Dr Sud Agarwal. It sells fixed-milestone pricing, claims costs 80–90% below US CROs and 30–60% below other Australian CROs, and about four-week ethics. In September 2025 it was named CRO for Sapu Nano's Sapu003 human trials.

    iNGENū CRO vs bioaccess®

    Dimension iNGENū CRO bioaccess®
    Core focus Lean Australian biotech CRO, drug-primary First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a lean US biotech looking for a low-cost Australian Phase 1, iNGENū is built for that.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including iNGENū CRO, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not iNGENū CRO features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the iNGENū CRO public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Accelagen Melbourne vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Accelagen into a search box, you are probably building a CRO shortlist. This article uses only what Accelagen publishes (accelagen.com.au) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Accelagen publishes

    Accelagen is a Melbourne regulatory and clinical firm founded in 2010 that can act as local sponsor. It markets to first-time and seed-stage sponsors of devices and small molecules. It publishes a case of ethics approval in 42 days for a US medical device company after two earlier rejections (sponsor not named), and first-in-human cases including Memo Therapeutics' anti-BKV therapy.

    Accelagen vs bioaccess®

    Dimension Accelagen bioaccess®
    Core focus Australian RA + CRO + local sponsor First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If this is your first Australian trial and you want regulatory, local sponsor and CRO in one boutique, Accelagen fits.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Accelagen, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Accelagen features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Accelagen public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Southern Star Research Sydney vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Southern Star Research into a search box, you are probably building a CRO shortlist. This article uses only what Southern Star Research publishes (southernstarresearch.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Southern Star Research publishes

    Southern Star Research is a Sydney CRO founded in 2010 that runs full-service Phase I–IV work, positioned around early-phase biotech plus medical device clients. It claims 4–8 week start-up through Phase I unit relationships. Lloyd Prescott is CEO and Dr David Lloyd is founder and Managing Director. We found no named sponsor first-in-human press release on its site.

    Southern Star Research vs bioaccess®

    Dimension Southern Star Research bioaccess®
    Core focus Boutique Australian Phase I–IV CRO First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a seed-to-Series B sponsor wanting an Australian specialist rather than a large CRO, Southern Star is a fair choice.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Southern Star Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Southern Star Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Southern Star Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Avance Clinical Australia vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Avance Clinical into a search box, you are probably building a CRO shortlist. This article uses only what Avance Clinical publishes (www.avancecro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Avance Clinical publishes

    Avance Clinical is an Adelaide-headquartered biotech CRO, formerly the clinical arm of CPR Pharma, with operations in Australia, New Zealand, Asia, North America and Europe. In January 2025 Avance said it was CRO of record on more than 52% of active Phase I trials on ANZCTR and that more than 80% of its clients are US biotechs. It runs an Early Phase Center of Excellence that places studies into Australian Phase I units.

    Avance Clinical vs bioaccess®

    Dimension Avance Clinical bioaccess®
    Core focus Biotech full-service CRO, early phase First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a US biotech running an Australian Phase I drug trial, Avance is one of the most established choices.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Avance Clinical, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Avance Clinical features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Avance Clinical public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Linear Clinical Research Perth vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Linear Clinical Research into a search box, you are probably building a CRO shortlist. This article uses only what Linear Clinical Research publishes (www.linear.org.au) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Linear Clinical Research publishes

    Linear Clinical Research is a not-for-profit Phase I and first-in-patient organization in Perth, founded in 2010 by the Harry Perkins Institute. It runs centres in Nedlands, Joondalup and an Advanced Clinical Trial Centre for next-generation and cell therapies. It claims 4–6 week ethics approval, a 75,000+ volunteer database and 94.5% of cohorts dosed on time in FY24. Its public work is medicines, vaccines and CAR-T.

    Linear Clinical Research vs bioaccess®

    Dimension Linear Clinical Research bioaccess®
    Core focus Drug Phase I + first-in-patient oncology / haematology First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a drug or cell-therapy sponsor that wants a fast Australian Phase I, Linear is a strong option.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Linear Clinical Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Linear Clinical Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Linear Clinical Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • CMAX Adelaide Phase I vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed CMAX Clinical Research into a search box, you are probably building a CRO shortlist. This article uses only what CMAX Clinical Research publishes (www.cmax.com.au) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What CMAX Clinical Research publishes

    CMAX Clinical Research is an independent Phase I–II unit in Adelaide, established in 1993, operating a 78-bed purpose-built facility on North Terrace opposite the Royal Adelaide Hospital. Its copy covers pharmaceutical, biotechnology and device companies. CMAX has published as a success story the first-ever human trial of Nacuity's NPI-001, run by its PI in 2017.

    CMAX Clinical Research vs bioaccess®

    Dimension CMAX Clinical Research bioaccess®
    Core focus Drug Phase I–II unit with unit-compatible device work First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need first-in-human for a drug or a simple device that needs confinement in a Phase I unit, CMAX is a credible choice.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including CMAX Clinical Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not CMAX Clinical Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the CMAX Clinical Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.